Immuron ceo, steven lydeamore to host an investor webinar

Melbourne, australia, feb. 15, 2023 (globe newswire) -- immuron limited (asx: imc; nasdq: imrn), an australian based and globally integrated biopharmaceutical company that has developed two commercially available oral immunotherapeutic products for the treatment of gut mediated diseases, invites investors to join a live webcast hosted by steven lydeamore, ceo of immuron limited.
IMRN Ratings Summary
IMRN Quant Ranking